Why is DMD community defending this company. SRPT deliberately avoided going through the FDA PhIII process.
SRPT could have easily followed two parallel paths:
1) They could have pursued approval on the 12 patient data and if over time it became unequivical the drug would be days away from approval. Unfortunately the data is NOT unequivocal.
2) They could have simultaneously pursued the PhIII trial which would be three years along by now, but they simply chose to roll the dice and delay, delay, delay...
The sufferers of DMD have my great sympathys, but from where I stand I would be seriously pizzzed at this company for avoiding the PhIII trial for so many years.
What the hey, if we are going to panic, lets do it right!
Internal controls issue because of new technology implementation.
No financial misstatements found.
Fire, fire, fire!!!!!!
Cramer says PHM should buy KBH just to get their building lots.
That would be great if PHM wanted to build $350K homes in $200K heighborhoods.
U go Jim!
Business is still in decline, debt is huge, still losing tons of money. Book value means little if they can't service the debt.
Future is very dependant on housing market. Then you have to throw in all the legal issues regarding past practices and ability (or lack of) to do business in key states.
Bottom line, the future is so extremely unpredictable that whomever has the loudest megaphone will move the stock in the near term.
CRASH AND BURN, FDA shoots surgibot down!
End of the line for TRXC
No cash, no revenue, and ALL THOSE NEW SALES PEOPLE TO PAY!
Sentiment: Strong Sell
Nevermind.... I've been listening to the conf call.... if you are thinking of shorting DY, you'd better listen to it.
Backlog is massive, the light rev/EPS are transient issues. Institutional holders will buy this dip.
Wouldn't be surprised if this thing ended the day positive.
By the way is their 'unnamed' customer Google?
Reported yesterday, midday. As someone else here said.... this thing is getting shot due to association with OCN.
LUXEMBOURG, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ:ASPS) today announces preliminary fourth quarter and full year 2015 results, capping off a year of strong performance with 2015 service revenue of $940.9 million, the best in the Company’s history. The Company’s preliminary 2015 diluted earnings per share, assuming the $80 million high end of the non-cash impairment charge described below, is estimated at $1.63. Adjusted diluted earnings per share(1) for 2015 is anticipated to be $6.96, near the high end of the Company’s 2015 financial scenarios.
“I am extremely pleased with our 2015 operating results with service revenue, adjusted pretax income(1) and adjusted diluted earnings per share(1) near the high end of our 2015 scenarios. As a testament to our success, we grew adjusted service revenue(1) unrelated to Ocwen and its portfolio by more than 40% in 2015. While our preliminary results include an impairment charge, the long term prospects for the Company remain strong and we are maintaining our 2016 financial scenarios,” said Chief Executive Officer William B. Shepro.
The thing about going long, you can only lose 100%.
You go short and you can wake up with a 300% loss the next day.
Can Streetsweeper recover, or will they be swept into the gutter of shortseller history?
So we doubled the stock buyback to $100MM from $50MM even though we haven't bought a single share since August authorization. Huh?
We only have $20MM on the bal sheet and $600MM in debt. Are we going to borrow more $$ to buy stock at all time highs?
On the conf call they said their two top customers will cut their usage of of AKAM services by 50% over the next year. It won't happen overnight, and will only have a modest effect on Mar qtr, but per the CEO will hit 'the next couple of quarters.
Analysts sounding cautious on the call and they don't look just to the next quarter, they have to look out a year. I'd expect analyst comments to be cautious.
Tomorrow will be a fun day, but after the big gap up, I say we end up flat (unless of course the market has a 3% up day!
I'm a skeptic, but I wouldn't short this stock based on Prescience Point report.
No smoking gun, just opinions on max number of stores and relative valuation.
Could have said the same things about Chipotle, Starbucks, etc...... a few years ago.
Need a real negative catalyst before this story ends.
Why, why, why did they put off for sooooo long, doing well designed PhII trial?
Yes some participants would recieve sham therapy, but it's the only way to prove whether it works..
What's the alternative? We fill every FDA AdComm with 100's of screaming patients (who in the future will be paid by the drug company) telling them to ignore science and approve a drug that may or may not work and charge the government $100K per year for it????? And where does that take us????
Holder Shares % Out Value* Reported
Omega Advisors Inc 1,662,462 7.61 46,233,066 Dec 31, 2015
Dude has hitched his horse to multiple blow-ups in the past few months. Probably him tanking the stock today.
Auditors put 'Going Concern' statements in 10k's all the time. All it means is that this company is likely to go bankrupt.
Sentiment: Strong Buy
So the FDA did a good job of crafting question 7 to prevent subjecting AdComm members to a bunch of emotions from desperate DMD sufferers & their families who would apporve drinking gasoline to treat DMD if SRPT told them that would help!
Took a lot of courage on the part of FDA to stand up to a tidal wave of emotion fomented by the greedy money mongers at SRPT.
Do the ffffoooooccckkkinggg trials SPRT!
To be clear, I'm not disparaging sphinctor lickers. If you're into feces for dinner in spite of all the health issues, thats your business.
I'm just saying that Cramer want's PHM to put up high cost houses in low cost neighborhoods. Not usually the best strategy for good profit margins.
Not that sphinctor licking seems to be the best long term strategy ether......................
You could have been half way through a solid Phase III trial by now if you didn't spend all of your money and time trying to garner sympathy and pull a fast one on the FDA.
Kudos to the FDA for standing their ground on SCIENCE! Not emotion and physchobabble!
My sympathies to those suffering from DMD. YOU more than anyone should be pizzzed off at the behavior of this company.
Sentiment: Strong Sell